Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2014 February 3; 124(2): 847–858.
Published online 2014 January 16. doi:  10.1172/JCI72241
PMCID: PMC3904628

Prion disease tempo determined by host-dependent substrate reduction


The symptoms of prion infection can take years or decades to manifest following the initial exposure. Molecular markers of prion disease include accumulation of the misfolded prion protein (PrPSc), which is derived from its cellular precursor (PrPC), as well as downregulation of the PrP-like Shadoo (Sho) glycoprotein. Given the overlapping cellular environments for PrPC and Sho, we inferred that PrPC levels might also be altered as part of a host response during prion infection. Using rodent models, we found that, in addition to changes in PrPC glycosylation and proteolytic processing, net reductions in PrPC occur in a wide range of prion diseases, including sheep scrapie, human Creutzfeldt-Jakob disease, and cervid chronic wasting disease. The reduction in PrPC results in decreased prion replication, as measured by the protein misfolding cyclic amplification technique for generating PrPSc in vitro. While PrPC downregulation is not discernible in animals with unusually short incubation periods and high PrPC expression, slowly evolving prion infections exhibit downregulation of the PrPC substrate required for new PrPSc synthesis and as a receptor for pathogenic signaling. Our data reveal PrPC downregulation as a previously unappreciated element of disease pathogenesis that defines the extensive, presymptomatic period for many prion strains.


Prions are transmissible agents responsible for incurable neurodegenerative diseases in humans and animals. Infection with prions is unique in that they may manifest after a lag phase that can exceed 5 decades from the time of exposure (1). The generation of infectivity from recombinant prion protein (PrP) (2) supports the “protein-only” hypothesis, whereby prion replication corresponds to a conformational transition from the host-encoded, cellular prion protein (PrPC) substrate into a misfolded infectivity-associated form called PrPSc. Initiation of prion disease has an obligatory dependence upon the introduction of a PrPSc “seed,” and susceptibility to disease is blocked by PrP gene null alleles (3). Prion disease pathogenesis is associated with a progressive accumulation of PrPSc levels, with the qualification that PrPSc may encompass subforms that are biophysically and perhaps toxicologically distinct (4, 5).

Besides PrPC, the Shadoo (Sho) glycoprotein is also expressed in the central nervous system. Sho has a similarity to the N-terminal region of PrP (6, 7) and interacts with several proteins that also interact with PrPC (8). While the function of Sho remains to be determined, a notable discovery was that levels of the Sho protein are reduced (downregulated) in prion disease (7, 9). Since this effect is apparent in the preclinical phase of disease (10, 11), we speculated that this phenomenon might be of broader importance for pathogenesis. In particular, the status of PrPC protein levels during prion infection has been investigated little, because of the unaltered steady-state levels of the corresponding mRNA (12, 13) and a co-occurrence of PrPSc that may be present in molar excess. Here, to investigate PrPC, while avoiding the confounding presence of PrPSc, velocity gradient centrifugation was used to separate monomeric PrPC from oligomeric and high molecular assemblies containing PrPSc (14). We then applied the conformation-dependent immunoassay (CDI), which measures a “hidden” epitope of PrPSc subsequent to its exposure by use of a chemical denaturant. By means of this 2-step procedure, we were able to analyze levels of different PrP species, including PrPC, protease-resistant PrPSc (rPrPSc), and protease-sensitive PrPSc (sPrPSc) (5). Our studies demonstrated both quantitative and qualitative alterations in PrPC, with a number of implications for our understanding of prion disease pathogenesis.


PrPC downregulation at end stage in scrapie, Creutzfeldt-Jakob disease, and chronic wasting disease models.

The procedure to couple velocity gradient centrifugation with CDI (as explained in the Introduction) has been validated previously for samples derived from hamsters (5) and humans (15). To extend this approach to the analysis of mouse PrP, we recalibrated conditions for the use of the monoclonal antibody 12B2 (mouse PrP epitope at residues 88–92) (ref. 16 and Figure Figure1,1, A and B). We then applied the recalibrated technique to the analysis of mouse brain homogenates; these homogenates were derived from WT mouse brains harvested at clinical end stage after infection with the Rocky Mountain Laboratory (RML) isolate of mouse-adapted scrapie prions. Our analyses demonstrated that 93% of the upper gradient fractions, fractions 9 and 10, are composed of PrPC, while rPrPSc and sPrPSc make up the remaining 7% (Figure (Figure1B).1B). Since PrPC is the predominant PrP isoform, we attempted to use the protein within these gradient fractions as a substrate in an in vitro assay to make PrPSc; this assay procedure is called protein misfolding cyclic amplification (PMCA) and is conceptually similar to PCR amplification of nucleic acids. However, proteins within the upper fractions of the velocity gradients were incompatible with our PMCA conditions and showed no detectable amplification, even though the levels of PrPC and concentrations of PrPSc after seeding with infected brain homogenate were comparable to the PMCA control experiment with nonfractionated material (Supplemental Figure 1; see complete unedited blots in the supplemental material; supplemental material available online with this article; doi: 10.1172/JCI72241DS1). Nonetheless, the low infectivity of these fractions, as determined by the standard scrapie cell assay (SSCA; a cell monolayer assay to determine the infectious titer for prions), supports the notion that the major component of these upper fractions is indeed PrPC (Figure (Figure1D).1D). In comparing RML prion-infected and noninfected animals, we discovered that total PrPC levels were decreased by 41% (P < 0.001) (Figure (Figure1B).1B). Interestingly, the PrP-like protein Sho was found in the same gradient fractions as PrPC, where it was also reduced in the RML-infected animals by approximately 48% of control values (P < 0.001) (Figure (Figure1,1, A and C).

Figure 1
Separation of PrP isoforms and prion infectivity by sedimentation velocity in sucrose gradient.

To determine whether PrPC downregulation is a broad-spectrum characteristic of prion infection, we applied similar analysis to end-stage brain material derived from WT mice infected with different strains of prions. Prion strains are microbiological isolates with distinct pathogenic properties that “breed true”; in molecular terms, they are thought to correspond to differently folded isoforms of PrPSc (17). For this purpose, we examined WT mice challenged with the 22L or 139A strains of scrapie prions, Syrian hamsters inoculated with the Sc237 scrapie prion strain, Tg cervid PrP (TgCe) mice (18) inoculated with chronic wasting disease (CWD) prions, Tg human PrP (TgHu) mice (19) challenged with a strain of human sporadic Creutzfeldt Jakob Disease (sCJD) prions, and bank voles inoculated with bank vole–adapted CWD prions. Our further analyses also included mice with a different genetic makeup. The most common allele of the mouse PrP gene (Prnp) is the Prnpa allele encoding PrPC-A. Here, we performed RML bioassays using mice that produce different levels of PrPC-A, which correspond to Tg mice expressing 0.53 times endogenous PrPC-A levels of WT mice (TgPrnpa-AL mice) and TgPrnpa mice (a widely used Tg, commonly referred to as tga20) overexpressing PrPC-A by approximately 6-fold (20). Excluding TgPrnpa mice and bank voles, marked decreases (P < 0.001) were noted in the net PrPC (primarily present in fractions 9 and 10 in infected brains; Supplemental Figures 1–6), and these decreases ranged from 31% ± 3.9% to 68% ± 8.4% (± SEM) (Figure (Figure2).2). As described for analyses with the RML prion isolate, Sho protein colocalized in fractions 9 and 10 with PrPC in 22L- and 139A-infected brain material from WT mice at levels 42%–48% of the control values (22L strain, P < 0.001; 139A strain, P < 0.01) (Supplemental Figure 1C).

Figure 2
PrPC downregulation as a common feature of prion disease.

PrPC quality is altered by prion infection.

For the 3 scrapie strains analyzed in WT mice (Figure (Figure1A1A and Supplemental Figure 1A), we were surprised to discover that residual PrPC present in infected animals exhibited an altered glycosylation profile. Generally, diglycosylated forms were underrepresented, and there were increased levels of monoglycosylated and unglycosylated PrPC bands in fractions 9 and 10 (versus the abundance of diglycosylated, monoglycosylated, and unglycosylated protein found in disease-free animals; Figure Figure3A).3A). In the next experiment, we used gel analysis to examine the upper velocity gradient fractions (fractions 10, 9, and 8) from the 3 mouse-adapted scrapie prion strains. For this purpose, samples were normalized according to PrP immunoblot signal when electrophoresed alongside equivalent gradient fractions from uninfected control animals. Protein samples were examined with or without PNGaseF deglycosylation (Figure (Figure3,3, B and C). Although low levels of proteinase K–resistant (PK-resistant) PrPSc (~8% of total rPrPSc and 2% of PrPC) were detected in each strain/host combination in the upper fractions of velocity gradients (Figure (Figure11 and Supplemental Figure 1), unexpectedly high amounts of the PrP C2 carboxyl-terminal fragment colocalized in the upper gradient fractions with protease-sensitive PrPC (Figure (Figure3,3, C and D). This is of interest because the C2 cleavage fragment is generally considered to be a rPrPSc product, not a PrPC product (21). Furthermore, comparison with the untreated samples indicates that this C2 fragment is primarily in its unglycosylated form (Figure (Figure33B).

Figure 3
Glycosylation and fragmentation of PrPC altered by prion infection.

Preclinical PrPC downregulation in infected WT mice.

As Sho downregulation occurs preclinically (10, 11), we next assessed a time course of WT mice challenged with RML prions or negative control inoculum. Levels of Sho and the different PrP species were analyzed, showing a coincident appearance of the disease-associated PrP C2 fragment and Sho reduction by 120 days after inoculation (dpi), a finding in line with previous reports (10) (Figure (Figure4,4, A and B). Using velocity gradient centrifugation plus CDI analysis on the time course series, rPrPSc began to increase by day 30 and continued to accumulate throughout the disease course (Figure (Figure5A),5A), a trend that paralleled a determination of infectious titer by scrapie cell assay in L929 cells (Figure (Figure4C).4C). However, these data illustrated a downturn for the rate of PrPSc replication at 60 dpi (Figure (Figure5A).5A). A biphasic profile was seen for PrPC in the infected mice, with a marked decrease beginning 60 dpi (Figure (Figure5B),5B), suggesting an inverse relationship to the aforementioned rPrPSc levels. This effect was even more noticeable, as it diverged from the slow rise in PrPC measured in aging mock-inoculated controls (Figure (Figure55B).

Figure 4
Time course analysis of control and pathogenesis-related proteins in infected mouse brain (RML isolate).
Figure 5
Preclinical drop in PrPC levels, Sho levels, and PrPSc replication rate.

In the interval of 60 to 140 dpi, PrPC levels in infected mice fell by over 40%, from 1,200 to 700 ng/ml. To ascertain whether the preclinical drop in PrPC levels was merely attributable to depletion of PrPC substrate to make new PrPSc, we fit the data deriving from CDI analyses of RML prion-infected animals with data obtained from our previous work on RML prion-infected bigenic mice (22). Specifically, the expression rate of PrPC (rE) was derived using the equation rE = ([PrPC]/2)/t1/2), where the half-lives (t1/2) for net brain PrPSc (i.e., sPrPSc plus rPrPSc) and brain PrPC were determined to be 36 hours and 18 hours, respectively (see Table Table11 and ref. 22). The accumulation rates (rA) of PrPSc and rPrPSc were then obtained by linear fit of the data at 90 to 140 dpi with RML isolate: PrPSc rA = –672 + (8.12 × time in days) (R = 0.99); rPrPSc rA = –62.4 + (0.77 × time in days) (R = 0.99). Clearance rates (rCL) of PrPSc and rPrPSc were calculated from the half-life of mouse PrPSc determined previously (22) in RML prion-infected doxycycline-regulated bigenics and accumulation rates of PrPSc and rPrPSc obtained in this study: rCL = (rA/2)/t1/2. Finally, the conversion rate (rC) of PrPC to PrPSc in the brain was determined from the accumulation rate of PrPSc corrected for clearance: rC = rA – rCL. According to these calculations, the expression rate of PrPC was estimated to be approximately 65-fold higher than the conversion rate to total PrPSc and approximately 700-fold higher than the conversion rate to rPrPSc, thus implying that depletion of PrPC for the synthesis of PrPSc is a negligible factor in determining the drop in steady-state levels of PrPC (i.e., downregulation). Also, speaking to degenerative changes, PrPC downregulation preceded alterations in the neuron marker NeuN, and we observed no changes in the GPI-linked Thy1.2 glycoprotein associated with caveolae (ref. 23 and Supplemental Figure 7).

Table 1
Relationship between expression rate of mouse PrPC and conversion rate to PrPSc after infection with RML prions

PrPC downregulation in models with different levels of starting PrPC.

Although prior studies have defined a profound effect of PrPC levels in healthy mice on disease incubation times subsequent to inoculation (24, 25), a downregulation effect was never considered in the interpretation of these studies. Consequently, we investigated prion infections in mice underexpressing or overexpressing PrPC.

To evaluate underexpression, we conducted a time course for RML prion-infected FVB/N hemizygous knockout (Prnp0/+) mice and controls inoculated with normal brain homogenate. Hemizygous Prnp0/+ mice are established as generating high levels of infectivity and PrPSc months before exhibiting symptoms of prion disease (26). To this effect, we observed that PrPSc began to accumulate in the brains of these animals between 60 and 100 dpi (Figure (Figure5C).5C). As in the case of WT animals, a parallel preclinical decrease in PrPC levels and PrPSc replication rate was observed in infected hemizygotes beginning at 100 dpi (nearly 300 days before the expected time in which they succumb to disease; ref. 26), and both parameters continued dropping throughout the time course, reaching levels approximately 40% lower than those of the controls (P < 0.001) (Figure (Figure5,5, C and D). This was accompanied by a gradual decrease in Sho throughout the duration of the time course (Figure (Figure5E).5E). While this cohort of animals has yet to reach disease end point, the effects of underexpression later in the disease course were explored using the TgPrnpa-AL mouse line made on a Prnp0/0 background and expressing 53% of WT levels of PrPC-A (Supplemental Figure 8). When measured in RML prion-infected mice at disease end point (400–430 dpi), the absolute PrPC levels in ng/ml lysate were downregulated to the lowest in our survey (Figure (Figure22).

Uninfected adult TgPrnpa mice overexpress 6 to 7 times PrPC levels of WT mice and have incubation periods of 60 to 80 dpi (20, 27). By CDI, the highest PrPC levels in uninfected TgPrnpa mice (C57BL6 background) were approximately 3 times those seen in WT FVB/N mice (Figure (Figure2A).2A). Infected TgPrnpa animals and normal brain homogenate inoculated controls were investigated in a time course series (Supplemental Figure 9, A–C). TgPrnpa animals were also discovered to exhibit a biphasic PrPC profile, albeit with a smaller effect size (11%, measured between 45 and 60 dpi), that was not significant due to the interindividual variability (±12%) (Supplemental Figure 9B). Nonetheless, a downturn in rPrPSc replication rate was noted when comparing the same 2 time points (Supplemental Figure 9A), offering an analogous trend to the effect noted in WT and hemizygous Prnp0/+ mice (Figure (Figure5,5, A and C). Like PrPC, Sho levels were affected little during the disease process in these mice (Supplemental Figure 9C).

These data suggest that notable effect sizes for PrPC downregulation are associated with long prion incubation times and vice versa. By plotting the incubation times of RML prions in these 3 hosts (all with the same Prnpa genotype but expressing different levels of PrPC) versus terminal concentrations of PrPC and rPrPSc, we found that prion infection caused a highly significant shift in the slope of the linear regression between incubation time of the disease and end point levels of PrPC (Figure (Figure6A6A and ref. 4). This shift in slope reflects a correlation for PrPC downregulation in the infected animals, with the largest difference in the data with or without infection occurring in the TgPrnpa-AL animals. A correlation was also apparent after plotting incubation time and the ratio between end point PrPC and rPrPSc (Figure (Figure6B).6B). Cumulatively, downregulation of PrPC was linked to the low expression levels of PrPC and high levels of the accumulated rPrPSc at disease end stage and is associated with prolonged incubation time (R = 0.99, P < 0.001). We next applied a similar plotting scheme to the spectrum of prion strains and disease models inoculated in our experiments. We found that this effect is broadly applicable despite independent variables that included 4 different Prnp genotypes, different starting PrPC levels, and 6 different strains of prions (Figure (Figure6C;6C; R = 0.77, P < 0.05).

Figure 6
Relationships between end point PrPC/PrPSc ratios and prion incubation period.

Assessing PrPC downregulation in bank voles.

Bank vole–adapted CWD prions produce the fastest prion disease in a naturally occurring animal host and hence are important in assessing the interplay between prion replication and disease pathogenesis (28). A time course series of samples was again investigated (Supplemental Figure 9, D–F). Unlike the other prion-infected specimens examined, PrPSc generated in the bank vole was primarily composed of oligomers sensitive to PK digestion (Supplemental Figure 6), a form that has been described as the most infectious PrP species (29). In this disease model, neither PrPC nor Sho levels differed between CWD- and mock-inoculated animals despite the low but continuous accumulation of rPrPSc observed in the brain 20 dpi (Supplemental Figure 9, E and F). However, a biphasic replication profile was again noted for rPrPSc, with a maximum increase from 20 to 25 dpi and steady decline during the final 5 days of disease (Supplemental Figure 9D). The short incubation period in CWD-infected bank voles may be related to the ability to rapidly generate PK-sensitive oligomers in the absence of Sho downregulation (Supplemental Figure 6 and Supplemental Figure 9F) (and PrPC downregulation) that may be typically triggered by rPrPSc (10, 11).

PrPC downregulation in cultured cells.

We wanted to investigate whether preclinical PrPC downregulation observed in vivo is associated with PrPSc accumulation (as previously demonstrated for Sho; refs. 10, 11) or is a side effect of neurodegenerative change. We explored this possibility using monocultures of cells that lack pathological signs upon prion infection (30). First, we compared N2a neuroblastoma expressing mouse PrPC-A (N2a) (31) and rabbit RK13-Gag cells expressing elk PrPC (RK13 Elk21) (32) chronically infected with RML prions or elk CWD prions, respectively. In both cases, corresponding PrPC reductions were approximately 35% and 55% compared with noninfected controls (Figure (Figure7,7, A and B). Next, to parallel in vivo time course experiments in the brain, we carried out de novo infections, monitoring RK13 cells stably expressing either mouse Prnpa or Prnpb for 5 weeks after treatment with RML-infected brain homogenate (Figure (Figure77 and Supplemental Figure 10). Similar infections with mouse-adapted scrapie prions in vivo have demonstrated drastically different susceptibilities for mice with these genotypes, where mice with the Prnpa genotype exhibit significantly shorter prion incubation periods than those with the Prnpb genotype (33). In parallel, expression of PrPC-A made RK13 cells highly susceptible to RML prion infection (Figure (Figure7,7, C and D; Supplemental Figure 10A; and refs. 25, 34). In comparison to mock-inoculated cells, propagation of PrPSc resulted in a decrease in PrPC until 21 dpi, with levels then recovering to control levels by 35 dpi (Figure (Figure7D).7D). The converted rPrPSc represented 0.3%–0.5% of homologous PrPC expressed in these cells. In contrast, RK13 cells expressing PrPC-B were resistant to infection (Figure (Figure7C7C and Supplemental Figure 10B). Since downregulation did not occur in cells expressing PrPC-B (Supplemental Figure 10C), the effect seen in Prnpa-expressing cells is not a response against administration of the brain homogenate but is instead a consequence of a productive infection. Cumulatively, the cell data provide evidence that neither neuronal loss accompanying prion disease nor conversion of PrPC to PrPSc can account, per se, for the PrPC downregulatory effect.

Figure 7
PrPC downregulation examined in cell culture models and by PMCA.

Impact of PrPC downregulation on prion replication rate.

Since prion replication rate decreased in tandem with PrPC downregulation in our time course studies, we investigated the relationship between these 2 events by simulating rPrPSc propagation during the prion infection process in vitro with PMCA (14, 35). First, we examined PMCA products for experiments seeded with increasing amounts of 139A prions in a constant amount of PrPC; here, PrPSc amplification was found to be a saturable component at PrPSc seed concentrations of ≥1 ng/ml (Supplemental Figure 11A). This may be analogous to the decreased PrPSc replication rate at end point prion disease in the absence of PrPC downregulation, as described above for TgPrnpa mice and bank voles. In experiments holding the RML PrPSc “seed” constant, dropping PrPC input in the range of 1,100 to 1,400 ng/ml (similar to the change in PrPC in early versus end stage disease in WT mice; Figure Figure5B)5B) had a marked impact upon replication rate (Supplemental Figure 11B), thus indicating that PrPC is a limiting factor, as previously reported (36). To simulate conditions more precisely over the course of prion infection, RML PrPSc seeds and PrPC substrate were inversely titrated to test the impact on amplification. At PrPC concentrations below approximately 350 ng/ml and PrPSc seed concentrations of ≥1 ng/ml PrPSc, the replication rate was held below an amplification index of 20-fold, apparently due to saturation with an abundance of PrPSc (Figure (Figure7E).7E). However, at higher ng/ml values of PrPC, these two traces diverge and hence are associated with a concomitant increase in replication rate, up to a factor of 110-fold (Figure (Figure7E).7E). These inverse titration experiments were extended to include 139A mouse-adapted prions (Supplemental Figure 11C), human sCJD prions (Supplemental Figure 11D), and Syrian hamster Sc237 prions (Supplemental Figure 11E). In every case, a uniform biphasic response was observed for each set of PMCA reactions, in which the most efficient amplification occurred in conditions paralleling an early stage of infection, with a low concentration of PrPSc and a high concentration of PrPC. Therefore, our PMCA data indicate that rising PrPSc levels and falling PrPC levels will converge to suppress prion replication. Furthermore, these results point to an affect of PrPC downregulation beginning halfway through the incubation time interval in WT mice (Figure (Figure55B).


Two unaddressed factors for prion infection are their long incubation periods and observed discrepancies between PrPSc levels and clinical disease (4, 37). However, using capture and conformational antibodies to inventory the different PrP species in the brain (i.e., rPrPSc, sPrPSc, and PrPC), we have defined a new variable in disease pathogenesis, namely preclinical downregulation of PrPC. This downregulation does not emanate from changes in PrP mRNA abundance (12, 13, 38).

PrPC is indisputably required for the creation of PrPSc (2, 3, 24), but depletion by the law of mass action (i.e., a finite pool of PrPC “substrate” being consumed by a thermodynamically favorable conversion to PrPSc) is implausible as the rate of PrPC synthesis in the brain outstrips the rate of formation of total PrPSc and rPrPSc by about 1 and 2 orders of magnitude, respectively (Table (Table1).1). It is also known from metabolic labeling of chronically infected cell cultures that only approximately 1% to 5% of PrPC converts into PrPSc (39, 40). Declining levels of PrPC in the course of protracted prion infections were in most instances shadowed by a drop in endogenous mouse Sho (refs. 10, 11; Figures Figures1,1, ,4,4, and and5;5; and Supplemental Figures 1 and 9), a cousin of PrPC that does not modulate creation of PrPSc and is not converted to a protease-resistant isoform (41). Depletion of PrPC as a simple consequence of synaptic damage or neuronal cell death is unlikely, because PrPC downregulation occurred nearly 300 days before clinical disease in hemizygous Prnp0/+ mice and was absent in certain rapid models with an abundance of vacuolation at end stage disease (i.e., TgPrnpa mice and bank voles; Figure Figure5D5D and Supplemental Figure 9, B and E). Moreover, PrPC downregulation was detected in cell culture models that are undergoing mitosis and have no synapses (Figure (Figure7,7, A–D). The recovery phase noted 2 weeks later in these de novo infections may reflect selection pressures operating within the cultures of infected but mitotically active cells. From these observations, we suggest first that a host protective response is operating at the level of a cellular biological mechanism, presumably a form of proteostasis. Second, we suggest this response is triggered by the presence of rPrPSc and reduces net levels of PrPC and Sho by a “bystander” effect (Figure (Figure88 and refs. 8, 10, 11). The reduction in net PrPC levels defined by our experiments stands in apparent contrast to a redistribution effect in persistently infected cells, in which cell surface PrP is reduced and immunohistochemical signal in a trans-Golgi network subcompartment is increased (42).

Figure 8
Summary of PrPC and Sho downregulation in a prion-infected cell by an unidentified degradation pathway.

Thus far, we have not identified the tell-tale signs of a single canonical proteostatic pathway, such as eIF-2αP (translation axis of the unfolded protein response) (43), LC3-II (autophagy), or ubiquitin (proteasome system) (Supplemental Figure 7). The largely parallel downregulation of PrPC and Sho indicates remodeling of a membrane microdomain that includes these proteins but does not include Thy-1.2 (Supplemental Figure 7A). However, the changes in the quality of PrPC (less diglycosylated, preponderance of C2 fragment) contrast with an across-the-board change that might be expected for a hypotheses of mass action depletion or cell death and were unexpected. The C2 aspect is especially notable as Watts and colleagues recently argued that Sho is degraded via an endocytic pathway that requires it to be physically trafficked with PrPSc (10). A component of this argument was the inverse correlation between Sho levels and the PrP C2 proteolytic fragment (10), with the latter hypothesized as a stable intermediate in the lysosomal degradation of PrPSc (44, 45). However, we have shown that models for other neurodegenerative diseases with activated lysosomes lack downregulation of Sho (11). Although our analyses of total cell lysates reaffirm a correlation between the reduction in Sho levels and the appearance of the protease-resistant PrP C2 proteolytic fragment toward disease end point (Figure (Figure4A),4A), our analyses of fractionated cell lysates demonstrated a surprising abundance of C2 colocalized in the upper gradient fractions. This suggests that protease-resistant C2 found toward disease end point derives from a protease-sensitive, and thus partly PrPC-like, precursor molecule. While the identity of an endoproteolytic “C2 PrPase” (like C1 PrPase; ref. 46) is unknown, progress in this area will help us to understand early events in PrPSc synthesis and early host responses. Another area of interest will be whether other parameters, such as a limited concentration of a cofactor (e.g., phosphatidylethanolamine; refs. 47, 48), can also contribute to a curtailment in the exponential phase for prion replication.

Prior studies have invoked a hypothetical toxic subform of PrP to explain the beneficial effects of a genetic reduction in PrPC levels that cause a delay between plateauing infectivity levels and the onset of clinical symptoms (4, 49). Here, an alternative explanation emerges from the observed changes with time in PrP isoforms. We show that the ratio between residual PrPC seen in end-stage disease and the amount of PrPSc is clearly correlated with the time lag to disease onset, and present experimental manipulations strongly suggest that this ratio in fact determines time lag. Within this formula, when PrPSc and infectivity reach a plateau (4), the extent of PrPC downregulation becomes the key variable. The difference between quickly and slowly evolving disease can be seen clearly in the different slopes shown in Figure Figure6A,6A, and we therefore suggest that the slowly evolving infection of the central nervous system (most typical of natural prion disease) can be seen to arise from downregulation of the very same substrate required both for de novo PrPSc synthesis and for pathogenic signaling, as defined by grafting experiments (50) and by use of regulated PrPC expression (49). Interestingly, while the need to hypothesize a toxic subform of PrPSc may be less urgent, PrPC downregulation can be reconciled with the measurements that led some to posit a 2-phase model for prion disease (4) or a form of substrate depletion predicted from analysis of prion disease kinetics (51). Cumulatively, our data show that slowly evolving pathogenesis of preclinical disease is caused by depletion of the PrPC substrate that is required for PrPSc synthesis and toxic signaling. We infer that the natural phenomenon of PrPC downregulation is partially effective in holding prion disease in check in WT animals. Drugs that enhance this protective response to further reduce PrPC may have a potent beneficial effect in treating prion disease.


Mouse lines, prion bioassays, and brain homogenates.

WT mice, hemizygous Prnp0/+ mice, TgPrnpa-AL mice expressing 53% WT levels of PrP-A and made by standard procedures using the PrP half-genomic construct (ref. 20 and see Supplemental Figure 8), TgPrnpa mice maintained as homozygous stock (20), humanized Tg40 mice (HuPrP-129M) (19), and cervidized Tg33 mice (Deer PrP-96G) (18) were used in this study. Mice were inoculated at 3 to 6 weeks of age with 30 to 50 μl 1% w/v brain homogenate containing mouse-adapted scrapie (RML, 22L, or 139A), MM1 sCJD (homozygous for methionine in polymorphic codon 129 of the PRNP gene and 21-kDa fragment [type 1] of unglycosylated rPrPSc on Western blots after PK treatment), or white-tailed deer CWD prions. Bank voles (Bv109I Prnp) were inoculated at 8 weeks of age with 20 μl brain homogenate containing bank vole–adapted elk CWD prions. For analysis, 10% w/v homogenate was made in PBS by serial passing through needles.

Sucrose gradient and CDI.

Sucrose gradient and CDI were performed as previously described (14). Briefly, the 400-μl aliquots of 10% brain homogenate in PBS, pH 7.4, containing 2% Sarkosyl were clarified by centrifugation at 500 g for 5 minutes and carefully layered onto the top of the 10% to 45% sucrose gradient prepared in PBS, pH 7.4, containing 1% Sarkosyl. Ultracentrifugation was performed at 237,000 g for 73 minutes at 5°C in an Optima TL ultracentrifuge (Beckman) equipped with a Beckman SW 55 Ti rotor. After the centrifugation, fractions were collected from the bottom of the tube.

The CDI assay was similar to previous descriptions (15, 52), albeit with several modifications. First, we used white Lumitrac 600 High-Binding Plates (E&K Scientific) coated with mAb 8H4 (epitope 175–185) (53) in 200 mM NaH2PO4 containing 0.03% (w/v) NaN3, pH 7.5. Second, 20-μl aliquots from each fraction containing 0.007% (v/v) of Patent Blue V (Sigma-Aldrich) were directly loaded into wells of white strip plates prefilled with 200 of Assay Buffer (Perkin Elmer). Finally, the captured PrP was detected by a europium-conjugated (5) anti-PrP mAb 3F4 (epitope 108–112) (54) or Europium-labeled mAb 12B2 (epitope 88–92) (16), and the time-resolved fluorescence (TRF) signals were measured by the multimode microplate reader PHERAstar Plus (BMG LabTech). The recombinant human PrP(90–231, 129M) and PrP(23–231, 129M) used as a calibrant in the CDI were a gift from Witold Surewicz (Department of Physiology and Biophysics, Case Western Reserve University), and preparation and purification have been described previously (55). The initial concentration of recombinant human PrP(23–231, 129M) and PrP(90–231, 129M) was calculated from absorbance at 280 nm and molar extinction coefficient 56,650 M–1cm–1 and 21,640 M–1cm–1, respectively. The purified recombinant proteins were dissolved in 4 M GdnHCl and 50% Stabilcoat (SurModics) and stored at –80 °C. The concentration of PrP was calculated from the CDI signal of denatured samples using a calibration curve prepared with either recombinant PrP(23–231, 129M) for samples containing full-length PrPSc or recombinant PrP(90–231, 129M) for samples containing truncated rPrPSc [PrP(27–30)] after PK treatment.

The calibration and validation aspect of CDI has been reported on extensively by us and others (5, 14, 15, 5662). Briefly, the PK-untreated sample containing PrP is divided into native and denatured aliquot, and the later is denatured with 4 M Gdn HCl for 5 minutes at 80°C. Using Eu-labeled mAb 3F4 or 12B2 for detection, the TRF signal of native sample corresponds to the epitope 107–112 that is exposed in α-helical PrPC and hidden in PrPSc and is proportional to the concentration of PrPC (5). The signal of denatured aliquot corresponds to the total PrP in a sample, and the concentration of PrPSc is then calculated according formula: [PrPSc] = [PrPD] – [PrPN], where D stands for denatured aliquot and N stands for native aliquot. Next, the concentration of rPrPSc is calculated in samples subjected to PK treatment followed by complete denaturation using PrP(90–231, 129M) calibration curve. The concentration of sPrPSc is calculated according formula: [sPrPSc] = [PrPSc] – [rPrPSc]. The separate calibration for the PK-treated and untreated sample is critical for correct results due to the approximately 3.5-fold lower affinity of mAb 3F4 with denatured full-length human PrP(23–231, 129M) compared to PrP(90–231, 129M) (14, 56).


SSCA was performed as described previously (63), with some modifications. Briefly, L929 cells were exposed to varying concentrations of brain homogenates (0.1–0.0001% w/v) for 5 days in 96-well culture plates. The cells were passaged 3 times (1:4 and 1:7), with 20,000 cells collected at the third passage and loaded on to MultiscreenHTS IP 96-well, 0.45-μM filter plates (Millipore). The cells were first subjected to PK digestion (5 μg/ml) followed by denaturation using 3 M guanidine thiocyanate. The Elispot reaction was performed using a mouse anti-PrP antibody (SAF83, 1:1,000) and a goat anti-mouse alkaline phosphatase–conjugated secondary antibody (1:5,000). The plates were developed using BCIP/NBT and analyzed using an Autoimmun Diagnostika GmbH Elispot plate reader (ELR07).


Sonication-driven PMCA was performed as described previously (14, 64) with the following modifications. The PrPSc was replicated using brains of homologous species or Tg mice expressing homologous PrPC (14). Brain homogenates from prion-infected animals were diluted as described in the specific experiments to attain final 10% brain homogenate, and 60 μl was transferred into 0.2-ml PCR tubes equipped with 2.38-mm diameter PTFE ball (K-mac Plastics). The buffer in all PMCA reactions was PBS, pH 7.4, containing final 1% Triton X-100, 500 mM NaCl, 0.1% Sarkosyl, and 1 mM of an antioxidant α-Tocopherol. Tubes were positioned on an adaptor placed on the plate holder of a microsonicator (Misonix Model 3000) and programmed to perform cycles of 60-minute incubation at 35°C, followed by a 30-second pulse of sonication set at 80% power. Samples were incubated, without shaking, and immersed in the water of the sonicator bath for 48 cycles. The 30 μl of the amplified materials was transferred to the next tube, which was prefilled with 30 μl substrate brain homogenate for the next round, and the remaining 30-μl aliquot was analyzed with CDI and Western blot analysis. The amplification index was calculated in each round using the following formula: [PMCA rPrPSc]/[seed rPrPSc].

Cell culture and infection with prions.

All RK13- and N2a-based cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (Invitrogen) containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C with 5% CO2. To obtain RK13 cell lines stably expressing mouse Prnpa and Prnpb, RK13 cells were transfected with 1 to 5 μg of specified clones in pBud.GFP (65) at approximately 90% confluence with the Lipofectamine Plus reagent (Invitrogen) according to the manufacturer’s specifications and selected in media supplemented with 1 mg/ml Zeocin. Prion infections were conducted under identical environmental conditions in 12-well plates containing Opti-Minimal Essential Medium supplemented with 25 μl 10% RML prion-infected or control brain homogenate as previously described (66).

Western blotting.

20–60 μg protein of each BCA-quantified (Pierce) sample was (a) deglycosylated overnight at 37°C with 250 to 500 U PNGaseF (New England Biolabs) and resuspended in gel-loading buffer (0.6 M Tris, pH 6.8; 2% SDS; 7.5% glycerol; 0.005% bromophenol blue; 2.5% β-mercaptoethanol); (b) digested with 100 μg/ml PK for 1 hour at 37°C, inactivated with 1 mM phenylmethylsufonylfluoride, and resuspended in gel-loading buffer; or (c) directly mixed with gel-loading buffer. Each was boiled for approximately 10 minutes and electrophoresed through 14% Tris–Glycine SDS-PAGE gels. Proteins were transferred onto a PVDF (Immobilon-FL, Millipore) membrane. Blots were incubated with anti-Sho 06rSh1, anti-PrP SHA31 (Medicorp Inc.), anti-PrP mAb 12B2 (16), anti-PrP mAbSAF83 (Cayman), anti-PrP mAb 2D6 (a generous gift from H. Rezai; ref. 67), anti-Thy1.2 (Abcam), anti–PSD-95 (Millipore), anti-NeuN (Millipore), anti-LC3 (Millipore), anti-Ubiquitin (Santa Cruz), and anti–Phospho-eIF2α (Cell Signaling Technology). ECL Plus reagents (Amersham Pharmacia) were used for visualization by exposure of blots to film or by scanning with an ImageQuant 300 (GE Healthcare). In some instances PNGaseF (NE Biolabs) was used per the manufacturer’s recommendations prior to blot analysis, and where appropriate, blots were reprobed with anti-actin primary antibody (Sigma-Aldrich) and anti-rabbit IgG secondary antibody conjugated to horseradish peroxidase. ImageJ software was utilized for densitometry analysis of the images (68).


All the statistical analyses were performed using SPSS 19 software (SPSS Inc.), and P values were calculated using Anova. P values of less than 0.05 were considered significant and are specified in the legend for each figure.

Study approval.

All protocols and experiments were approved by the IACUC of the Case Western Reserve University and University of Alberta.

Supplementary Material

Supplemental data:


We thank Witold Surewicz for recombinant PrP used for calibration in CDI, Earl Poptic from Cleveland Clinic Hybridoma Core Facility for production of 8H4 mAb, and R. Kascsak, H. Rezai, and S. Kar for providing antibodies. We thank F. Jirik (University of Calgary, Calgary, Alberta, Canada) and V. Sim (University of Alberta) for breeding pairs of TgPrnpa mice. This work was supported by grants from NINDS (NS074317), CDC (UR8/CCU515004), the Charles S. Britton Fund, the Canada Foundation for Innovation, the Canadian Institutes of Health Research (MOP36377), the Alberta Prion Research Institute, and Alberta Innovates — Health Solutions for graduate and postgraduate funding for A. Lau and C.E. Mays and a Scientist award to D. Westaway.


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2014;124(2):847–858. doi:10.1172/JCI72241.


1. Collinge J, et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci. 2008;363(1510):3725–3739. doi: 10.1098/rstb.2008.0068. [PMC free article] [PubMed] [Cross Ref]
2. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science. 2010;327(5969):1132–1135. doi: 10.1126/science.1183748. [PMC free article] [PubMed] [Cross Ref]
3. Büeler H, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73(7):1339–1347. doi: 10.1016/0092-8674(93)90360-3. [PubMed] [Cross Ref]
4. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011;470(7335):540–542. doi: 10.1038/nature09768. [PubMed] [Cross Ref]
5. Safar J, et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med. 1998;4(10):1157–1165. doi: 10.1038/2654. [PubMed] [Cross Ref]
6. Premzl M, Sangiorgio L, Strumbo B, Marshall Graves JA, Simonic T, Gready JE. Shadoo, a new protein highly conserved from fish to mammals and with similarity to prion protein. Gene. 2003;314:89–102. doi: 10.1016/S0378-1119(03)00707-8. [PubMed] [Cross Ref]
7. Watts JC, et al. The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J. 2007;26(17):4038–4050. doi: 10.1038/sj.emboj.7601830. [PMC free article] [PubMed] [Cross Ref]
8. Watts JC, et al. Interactome analyses identify ties of PrP and its mammalian paralogs to oligomannosidic N-glycans and endoplasmic reticulum-derived chaperones. PLoS Pathog. 2009;5(10):e1000608. doi: 10.1371/journal.ppat.1000608. [PMC free article] [PubMed] [Cross Ref]
9. Miyazawa K, Manuelidis L. Agent-specific Shadoo responses in transmissible encephalopathies. J Neuroimmune Pharmacol. 2010;5(1):155–163. doi: 10.1007/s11481-010-9191-1. [PMC free article] [PubMed] [Cross Ref]
10. Watts JC, et al. Protease-resistant prions selectively decrease shadoo protein. PLoS Pathog. 2011;7(11):e1002382. doi: 10.1371/journal.ppat.1002382. [PMC free article] [PubMed] [Cross Ref]
11. Westaway D, et al. Down-regulation of shadoo in prion infections traces a pre-clinical event inversely related to PrPSc accumulation. PLoS Pathog. 2011;7(11):e1002391. doi: 10.1371/journal.ppat.1002391. [PMC free article] [PubMed] [Cross Ref]
12. Chesebro B, et al. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature. 1985;315(6017):331–333. doi: 10.1038/315331a0. [PubMed] [Cross Ref]
13. Oesch B, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 1985;40(4):735–746. doi: 10.1016/0092-8674(85)90333-2. [PubMed] [Cross Ref]
14. Kim C, et al. Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrPC. PLoS Pathog. 2012;8(8):e1002835. doi: 10.1371/journal.ppat.1002835. [PMC free article] [PubMed] [Cross Ref]
15. Safar JG, et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A. 2005;102(9):3501–3506. doi: 10.1073/pnas.0409651102. [PubMed] [Cross Ref]
16. Langeveld JPM, Jacobs JG, Erkens JHF, Bossers A. Rapid and discriminatory diagnosis of scrapie and BSE in retro-pharyngeal lymph nodes of sheep. BMC Vet Res. 2006;9:19. doi: 10.1186/1746-6148-9-19. [PMC free article] [PubMed] [Cross Ref]
17. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930–936. doi: 10.1126/science.1138718. [PubMed] [Cross Ref]
18. Meade-White K, et al. Resistance to Chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol. 2007;81(9):4533–4539. doi: 10.1128/JVI.02762-06. [PMC free article] [PubMed] [Cross Ref]
19. Kong Q, et al. Chronic wasting disease of elk: Transmissibility to humans examined by transgenic mouse models. J Neurosci. 2005;25(35):7944–7949. doi: 10.1523/JNEUROSCI.2467-05.2005. [PubMed] [Cross Ref]
20. Fischer M, et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996;15(6):1255–1264. [PubMed]
21. Chen SG, Teplow D, Parchi P, Gambetti P, Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem. 1995;270(32):19173–19180. doi: 10.1074/jbc.270.32.19173. [PubMed] [Cross Ref]
22. Safar JG, et al. Prion clearance in bigenic mice. J Gen Virol. 2005;86(pt 10):2913–2923. doi: 10.1099/vir.0.80947-0. [PubMed] [Cross Ref]
23. Sheets ED, Lee GM, Simson R, Jacobson K. Transient confinement of a glycosylphosphatidylinositol-anchored protein in the plasma membrane. Biochemistry. 1997;36(41):12449–12458. doi: 10.1021/bi9710939. [PubMed] [Cross Ref]
24. Prusiner SB, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell. 1990;63(4):673–686. doi: 10.1016/0092-8674(90)90134-Z. [PubMed] [Cross Ref]
25. Carlson GA, et al. Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci U S A. 1994;91(12):5690–5694. doi: 10.1073/pnas.91.12.5690. [PubMed] [Cross Ref]
26. Büeler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann C. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med. 1994;1(1):19–30. [PMC free article] [PubMed]
27. Castro-Seoane R, et al. Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection. PLoS Pathog. 2012;8(2):e1002538. doi: 10.1371/journal.ppat.1002538. [PMC free article] [PubMed] [Cross Ref]
28. Di Bari MA, et al. Chronic wasting disease in bank voles: Characterisation of the shortest incubation time model for prion diseases. PLoS Pathog. 2013;9(3):e1003219. doi: 10.1371/journal.ppat.1003219. [PMC free article] [PubMed] [Cross Ref]
29. Silveira JR, et al. The most infectious prion protein particles. Nature. 2005;437(7056):257–261. doi: 10.1038/nature03989. [PMC free article] [PubMed] [Cross Ref]
30. Vilette D. Cell models of prion infection. Vet Res. 2008;39(4):10. doi: 10.1051/vetres:2007049. [PubMed] [Cross Ref]
31. Klebe RJ, Ruddle FH. Neuroblastoma: cell culture analysis of a differentiating stem cell system. J Cell Biol. 1969;43(2):69a. [PubMed]
32. Bian J, Napier D, Khaychuck V, Angers R, Graham C, Telling G. Cell-based quantification of chronic wasting disease prions. J Virol. 2010;84(16):8322–8326. doi: 10.1128/JVI.00633-10. [PMC free article] [PubMed] [Cross Ref]
33. Carlson GA, et al. Linkage of prion protein and scrapie incubation time genes. Cell. 1986;46(4):503–511. doi: 10.1016/0092-8674(86)90875-5. [PubMed] [Cross Ref]
34. Westaway D, Goodman PA, Mirenda CA, McKinley MP, Carlson GA, Prusiner SB. Distinct prion proteins in short and long scrapie incubation period mice. Cell. 1987;51(4):651–662. doi: 10.1016/0092-8674(87)90134-6. [PubMed] [Cross Ref]
35. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–813. doi: 10.1038/35081095. [PubMed] [Cross Ref]
36. Mays CE, Titlow W, Seward T, Telling GC, Ryou C. Enhancement of protein misfolding cyclic amplification by using concentrated cellular prion protein source. Biochem Biophys Res Commun. 2009;388(2):306–310. doi: 10.1016/j.bbrc.2009.07.163. [PMC free article] [PubMed] [Cross Ref]
37. Bueler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann C. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med. 1994;1(1):19–30. [PMC free article] [PubMed]
38. Aguib Y, Gilch S, Krammer C, Ertmer A, Groschup MH, Schatzl HM. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc. Mol Cell Neurosci. 2008;38(1):98–109. doi: 10.1016/j.mcn.2008.02.004. [PubMed] [Cross Ref]
39. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem. 1991;266(27):18217–18223. [PubMed]
40. Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem. 1992;267(9):6188–6199. [PubMed]
41. Daude N, et al. Knockout of the prion protein (PrP)-like Sprn gene does not produce embryonic lethality in combination with PrPC-deficiency. Proc Natl Acad Sci U S A. 2012;109(23):9035–9040. doi: 10.1073/pnas.1202130109. [PubMed] [Cross Ref]
42. Uchiyama K, Muramatsu N, Yano M, Usui T, Miyata H, Sakaguchi S. Prions disturb post-Golgi trafficking of membrane proteins. Nat Commun. 2013;4:1846. doi: 10.1038/ncomms2873. [PubMed] [Cross Ref]
43. Moreno JA, et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature. 2012;485(7399):507–511. [PMC free article] [PubMed]
44. Taraboulos A, Raeber AJ, Borchelt DR, Serban D, Prusiner SB. Synthesis and trafficking of prion proteins in cultured cells. Mol Biol Cell. 1992;3(8):851–863. doi: 10.1091/mbc.3.8.851. [PMC free article] [PubMed] [Cross Ref]
45. Dron M, et al. Endogenous proteolytic cleavage of disease-associated prion protein to produce C2 fragments is strongly cell- and tissue-dependent. J Biol Chem. 2010;285(14):10252–10264. doi: 10.1074/jbc.M109.083857. [PMC free article] [PubMed] [Cross Ref]
46. Oliveira-Martins JB, Calella AM, Bridel C, Baumann F, Dametto P, Aguzzi A. Unexpected tolerance of α-cleavage of the prion protein to sequence variations. PLoS One. 2010;5(2):e9107. doi: 10.1371/journal.pone.0009107. [PMC free article] [PubMed] [Cross Ref]
47. Deleault NR, et al. Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A. 2012;109(22):8546–8551. doi: 10.1073/pnas.1204498109. [PubMed] [Cross Ref]
48. Deleault NR, et al. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A. 2012;109(28):1938–1946. doi: 10.1073/pnas.1206999109. [PubMed] [Cross Ref]
49. Mallucci GR, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron. 2007;53(3):325–335. doi: 10.1016/j.neuron.2007.01.005. [PubMed] [Cross Ref]
50. Brandner S, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996;379(6563):339–343. doi: 10.1038/379339a0. [PubMed] [Cross Ref]
51. Aguzzi A, Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci. 2012;15(7):936–939. doi: 10.1038/nn.3120. [PubMed] [Cross Ref]
52. Choi EM, et al. Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease. Lab Invest. 2009;89(6):624–635. doi: 10.1038/labinvest.2009.30. [PMC free article] [PubMed] [Cross Ref]
53. Zanusso G, et al. Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A. 1998;95(15):8812–8816. doi: 10.1073/pnas.95.15.8812. [PubMed] [Cross Ref]
54. Kascsak RJ, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987;61(12):3688–3693. [PMC free article] [PubMed]
55. Swietnicki W, Morillas M, Chen SG, Gambetti P, Surewicz WK. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry. 2000;39(2):424–431. doi: 10.1021/bi991967m. [PubMed] [Cross Ref]
56. Kim C, et al. Protease-sensitive conformers in broad spectrum of distinct PrPSc structures in sporadic Creutzfeldt-Jakob Disease are indicator of progression rate. PLoS Pathog. 2011;7(9):e1002242. doi: 10.1371/journal.ppat.1002242. [PMC free article] [PubMed] [Cross Ref]
57. Safar JG, et al. Transmission and detection of prions in feces. J Infect Dis. 2008;198(1):81–89. doi: 10.1086/588193. [PMC free article] [PubMed] [Cross Ref]
58. Safar JG, et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotech. 2002;20:1147–1150. doi: 10.1038/nbt748. [PubMed] [Cross Ref]
59. Thackray AM, Hopkins L, Bujdoso R. Proteinase K-sensitive disease-associated ovine prion protein revealed by conformation-dependent immunoassay. Biochem J. 2007;401(2):475–483. doi: 10.1042/BJ20061264. [PubMed] [Cross Ref]
60. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Gröner A, Vey M. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol. 2003;84(pt 7):1921–1925. doi: 10.1099/vir.0.18996-0. [PubMed] [Cross Ref]
61. Choi YP, Gröner A, Ironside JW, Head MW. Comparison of the level, distribution and form of disease-associated prion protein in variant and sporadic Creutzfeldt–Jakob diseased brain using conformation-dependent immunoassay and Western blot. J Gen Virol. 2011;92(pt 3):727–732. doi: 10.1099/vir.0.026948-0. [PubMed] [Cross Ref]
62. McCutcheon S, Hunter N, Houston F. Use of a new immunoassay to measure PrPSc levels in scrapie-infected sheep brains reveals PrP genotype-specific differences. J Immunol Methods. 2005;298(1–2):119–128. doi: 10.1016/j.jim.2005.01.012. [PubMed] [Cross Ref]
63. Mahal SP, Baker CA, Demczyk CA, Smith EW, Julius C, Weissmann C. Prion strain discrimination in cell culture: The cell panel assay. Proc Natl Acad Sci U S A. 2007;104(52):20908–20913. doi: 10.1073/pnas.0710054104. [PubMed] [Cross Ref]
64. Castilla J, Morales R, Saá P, Barria M, Gambetti P, Soto C. Cell-free propagation of prion strains. EMBO J. 2008;27(19):2557–2566. doi: 10.1038/emboj.2008.181. [PubMed] [Cross Ref]
65. Drisaldi B, et al. Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrPC offset pro-apoptotic activity of the doppel helix B/B’ region. J Biol Chem. 2004;279(53):55443–55454. doi: 10.1074/jbc.M404794200. [PubMed] [Cross Ref]
66. Vilette D, et al. Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc Natl Acad Sci U S A. 2001;98(7):4055–4059. doi: 10.1073/pnas.061337998. [PubMed] [Cross Ref]
67. Moudjou M, et al. Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie. J Virol. 2004;78(17):9270–9276. doi: 10.1128/JVI.78.17.9270-9276.2004. [PMC free article] [PubMed] [Cross Ref]
68. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation